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Neurodegenerative diseases (NDs) are chronic degenerative diseases of the central nervous system (CNS), which
affect 37 million people worldwide. As the lifespan increases, the NDs are the fourth leading cause of death in the
developed countries and becoming increasingly prevalent in developing countries. Despite considerable research,
the underlying mechanisms remain poorly understood. Although the large majority of studies do not show support
for the involvement of pathogenic aetiology in classical NDs, a number of emerging studies show support for
possible association of viruses with classical neurodegenerative diseases in humans. Space does not permit for
extensive details to be discussed here on non-viral-induced neurodegenerative diseases in humans, as they are well
described in literature.
Viruses induce alterations and degenerations of neurons both directly and indirectly. Their ability to attack the host
immune system, regions of nervous tissue implies that they can interfere with the same pathways involved in
classical NDs in humans. Supporting this, many similarities between classical NDs and virus-mediated
neurodegeneration (non-classical) have been shown at the anatomic, sub-cellular, genomic and proteomic levels
suggesting that viruses can explain neurodegenerative disorders mechanistically. The main objective of this review
is to provide readers a detailed snapshot of similarities viral and non-viral neurodegenerative diseases share, so that
mechanistic pathways of neurodegeneration in human NDs can be clearly understood. Viruses can guide us to
unveil these pathways in human NDs. This will further stimulate the birth of new concepts in the biological
research, which is needed for gaining deeper insights into the treatment of human NDs and delineate mechanisms
underlying neurodegeneration.
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Amyotrophic lateral sclerosisNeurodegenerative diseases are chronic degenerative
diseases of the central nervous system (CNS) resulting
from neurodegenerative processes. They are character-
ized by chronic progressive loss of structure and func-
tion of neurons. They are increasingly common
disorders, which strike in mid-to-late adult life. They
affect 37 million people worldwide and are the fourth
leading cause of death in the developed countries and
are becoming increasingly significant in the developing
countries as well. The incidence rate is expected to be-
come higher as the lifespan increases. Despite intensive
research, the underlying causes of most neurodegenerative
diseases remain poorly understood. Several intracellular
mechanisms are involved in classical neurodegenerative* Correspondence: nitin.saksena@sydney.edu.au
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reproduction in any medium, provided the ordiseases: protein degradation, mitochondrial dysfunction,
defective axonal transport and apoptosis. The pathological
mechanisms underlying neurodegenerative disorders in
humans have gained renewed attention, not only because
human NDs are growing cause of concern and disability
in ageing humans globally in ageing humans, but also
in part due to the evolving nature of NDs in humans,
possible pathogen involvement and recent evidence
from proteomic and genomic fronts showing similar-
ities between virally-induced NDs and classical NDs
in humans [1-3].
Immune activation within the central nervous system
(CNS) is classically observed in several immune-
mediated disorders, viral infections and also in human
neurodegenerative diseases. Although, often the immune
responses may contribute directly or indirectly to neuronal
damage, not all immune responses in the CNS are
damaging because they assist in repair and regeneration.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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underlying pathogenic process, which may shift the
delicate balance between beneficial and detrimental
response [2,3].
As global research on neurodegenerative diseases pro-
gresses on various fronts, many similarities between
classical neurodegenerative diseases and virus-mediated
neurodegeneration are becoming apparent at both
anatomic and sub-cellular level [1,4,5]. Supporting these
observations, a number of viruses have been shown to
be associated with different types of neurodegenerative
diseases, which can guide us underpin mechanisms in
neurodegeneration (Table 1). We know that neurotropic
viruses are able to induce considerable neuronal dys-
function by inducing alterations and degenerations of
neurons both directly and indirectly leading toTable 1 Association of viruses and neurodegeneration
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view is to provide a detailed and a unique snapshot of
how viruses lead to neurodegeneration in humans and
their possible involvement in classical human NDs,
which will shed light not only on a profound under-
standing of viruses as mediators or modulators of neuro-
degenerative diseases, but also on the development of
future strategies to treat them.
Viral association in human NDs
a. Herpesviridae and their association with Alzheimer’s
disease (AD) (herpes simplex virus-1(HSV-1 type HHV-1)
HSV-1 is one of the most common viruses in the general
population and can cause latent infection in neurons for
life-long. It belongs to the family Herpesviridae, which is
a large family of double-stranded DNA viruses [32,33].
HSV-1 is neurotropic and neuro-invasive with high
neuro-virulence and grows well in vitro in both neuronal
cell lines and dorsal root ganglia. Primary sympathetic
neuronal cultures support HSV-1 infections, which re-
semble natural latency. In vivo, HSV-1 establishes life-
long latency in peripheral neurons where productive
replication is suppressed. While periodic reactivation re-
sults in productive infection, the molecular, genomic and
proteomic basis of neuronal latency remains poorly
understood.
AD is the most common form of dementia. There are
26.6 million patients suffering AD worldwide and
according to the World Health Organization, the preva-
lence would increase to 0.441% by 2015 and to 0.556%
by 2030 (WHO). Because it can’t be cured, it is one of
the most expensive diseases to manage and treat in the
developed countries [34]. AD is characterized by loss of
neurons and synapses in the cerebral cortex and certain
subcortical regions. One of the most notable patho-
logical features is the appearance of plaques and tangles
of neurofibrils within brain nerves. AD has been identi-
fied as a protein mis-folding disease as both plaques and
tangles involve the deposition and accumulation of
abnormally folded A-beta and tau proteins [35,36]. Pre-
cisely how the disturbances of production and aggrega-
tion of the beta-amyloid peptide leads to the pathology
of AD is poorly understood. The amyloid hypothesis
suggests the accumulation of beta-amyloid peptides as
the central event triggering neuron degeneration. Accu-
mulation of aggregated amyloid fibrils, which are be-
lieved to be the toxic form of the protein responsible for
disrupting the cell’s calcium ion homeostasis, induces
programmed cell death (apoptosis) [37]. It is also known
that βamyloid selectively builds up in the mitochondria
in the cells of Alzheimer’s-affected brains, and it also in-
hibits certain enzyme functions and the utilization of
glucose by neurons[38]. In addition, various inflamma-
tory processes and cytokines possibly play significantrole in the pathology of Alzheimer’s disease. Inflamma-
tion is indicative of tissue damage in any disease, but it
is likely that it may be a marker of an immunological re-
sponse [39]. Yet, the precise cause of AD is not well
understood and recently brain infections have been sug-
gested as a possible trigger or cofactor(s) in AD. Several
viruses have been linked to AD (Table 1), with HSV-1
being the most popular and well studied in relation to AD.
The presence of HSV-1 DNA in elder brain, especially
for APOE gene carriers, is a risk factor for AD [40]. Its
seropositivity reactivation has also been shown to signifi-
cantly correlate with incident AD [41]. Furthermore,
HSV-1 infection in AD brain has been detected by elec-
tron microscopy and immunohistochemistry in a rapid
progressor with AD, indicating the significant role of re-
activation of HSV in AD progression [42]. In addition,
Wozniak et al., has further demonstrated the role of
HSV-1 in AD by localizing HSV-1 DNA in amyloid
plaques and detected higher association between viral
DNA and Amyloid beta plaques in AD patients’ brains
compared to normal ageing brains (72% versus 24%,
p<0.001), suggesting HSV-1 to be a possible major cause
of amyloid plaques and a possible etiological factor in AD
[43]. Moreover, short contiguous amino acid stretches in
proteins expressed by HSV are homologous to APOE4,
clusterin, and many other gene products highly relevant to
AD, also suggesting the role of HSV as a causative agent
that is involved in AD development [44].
The possible mechanisms by which HSV-1 triggers
AD have been studied in some detail. It has been found
that isolated intracellular HSV1 particles physically asso-
ciated with amyloid precursor protein (APP), through
which the viruses exploit to travel to the cell surface
[45,46]. APP is an integral membrane protein highly
expressed in the synapses of neurons and best known as
the precursor molecule whose proteolysis generates beta
amyloid (Aβ). Abnormal deposition and accumulation of
Aβ and tau proteins serves as the primary cause of
plaques and tangles formation, which is one of the most
notable pathological features in the AD brain [35,36].
Cheng et al., has further proven that HSV1 is specifically
co-localized with APP to facilitate viral transport and
also alters normal APP transport, distribution, and even
microtubule networks and their stability [47]. HSV-1 in-
fection has also been shown to promote neurotoxic Aβ ac-
cumulation [48-50], tau phosphorylation [51] and cleavage
[52] in vitro. Apart from direct interaction, HSV1 infection
has also been found to interfere with post-transcriptional
regulation by up regulating microRNA-146a, which is
significantly involved in AD [53].
With the compelling evidence of HSV-1 association
with AD, HSV-1 infection in people over 50 years of age
is definitely a risk factor or co-factor at least in AD.
Therefore, it remains to be seen if the administration of
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effect on improvement and general well being of patients
with AD. This may provide a further confirmation of
HSV-1 involvement in AD.
b. Multiple sclerosis (MS) and its relationship with the
roseolovirus (type HHV-6), eppstein Barr virus (EBV type
HHV-4) and varicella zoster virus (VZV type HHV3)
Roseolovirus (HHV-6)
MS, commonly known as a chronic inflammatory de-
myelinating disease of the CNS, is the most common
cause of neurological disability in young adults. It re-
cently has been classified as neurodegenerative diseases
due to: 1. The axonal loss and dysfunction occuring at
very early stages of MS [54]; 2. The clinical disability of
MS correlates better with the extent of total axonal
damage, loss and brain atrophy [55-57]; and 3. Critical
loss of axon density during disease progression [58,59].
It has four clinical subtypes, among which relapsing-
remitting subtype describes the initial course of 80% of
individuals with MS [60]. Although the mechanisms in
MS disease process are well known, the underlying
causes remain poorly understood. Unlike other neurode-
generative diseases, MS might be a consequence of a
combination of genetic, environmental and possibly in-
fectious factors, but so far no plausible explanation has
proven definitive. In this context it is important to men-
tion that viruses have long been suggested to be involved
in the etiology of MS [61].
Among the most well described viruses, growing body
of evidence suggests that HHV-6 can play a direct and
an indirect role in MS either as an activator of viruses
such as EBV and human endogenous retrovirus-W
(HERV-W). Noteworthy is its ability to infect almost
100% of the general population worldwide [62] and
remain latent in approximately 90% of the adults [63].
Although it remains rare in causing primary infections
in adults, and the re-activation is often asymptomatic in
the immuno-competent setting, it can trigger serious
complications in immunosuppressed patients [64].
HHV6 protein is reported to be expressed in oligoden-
drocytes in active MS plaques [65]. Recently, Alvarez-
Lafuente et al., also showed HHV-6 DNA in the spinal
fluid of a subset of MS patients more frequently than in
those with other neurological disease [66]. In support of
these findings, it has been shown that HHV-6 serum
DNA levels diminish with interferon-β treatment and
patients who do not clear HHV-6 infection during inter-
feron therapy have a poor prognosis [67]. The virus is
known to periodically re-activate from its latent state
and Chapenko et al., have shown a significant associ-
ation between HHV-6 infection and MS in addition to a
correlation between HHV-6 reactivation and disease ac-
tivity in relapsing/remitting and secondary progressiveMS [68]. In addition, HHV-6 presents more frequently
in blood and serum during relapses compared to during
remission and this, in turn, correlates with higher risk of
severe relapse and poor response to interferon-β therapy
[67]. Further, increased IgM serum antibody responses
to HHV-6 early antigen (p41/38) in patients with
relapsing-remitting MS (RRMS), compared to patients
with chronic progressive MS (CPMS), other neurologic
diseases (OND and autoimmune diseases (OID), and
normal controls have been demonstrated. Interestingly
these antibody studies were further supported by the de-
tection of HHV-6 DNA from samples of MS serum indi-
cating active viral infection [69]. Furthermore, the
validity of connection between HHV6 and MS has also
been replicated in animal models. Investigators from the
UCSF and the NINDS induced brain lesions and MS-
type ambulatory deficits in marmosets after exposing
them to intranasal injections of HHV-6A virus [70,71].
Recently, Vandenbroeck et al., [72] analyzed IRF5 poly-
morphisms rs4728142 and rs3807306 in MS predispo-
sition, by combining the five European datasets, which
include three Spanish replication cohorts. Combining
these datasets have shown that the T allele of rs3807306
is a significant marker for both susceptibility to MS and
infection with HHV-6 and also constitutes a promising
marker for response to IFN-β therapy. This study also
suggests complex interactions centering on the IRF5
gene, which, upon further investigation may help in
understanding the interplay between genes and virus in
predisposition to MS [72]. In this context, it is important
to recall that HHV-6 has been reported to be associated
with MHC class II transactivator (MHC2TA) rs4774C
(MHC2TA rs4774C and HHV-6A)[73]. Further stressing
the role of virus in MS in manipulating the host immune
system is the evidence for lymphoproliferative responses
to HHV-6A together with the evolution of lesions in
MRI in relation to HHV-6 infection has been found in
MS patients [74], which appears to be greater in MS pa-
tients (67%) than in controls (32%). Such observations
are critical in tracing the possible links of a pathogenic
etiology in MS.
EBV (HHV-4)
Epstein-Barr virus (EBV), another neurotropic virus in
the HHV family, has been first linked to MS in 1979 by
Fraser and colleagues, demonstrating increased tendency
of peripheral blood lymphocytes from active MS patients
toward spontaneous in vitro EBV-induced B lymphocyte
transformation [75]. Over 90% of all populations get
infected within the first decades of life with EBV, which
can latently persist in B-lymphocytes for the lifetime of
the human host. The higher risk has been reported when
EBV seroconversion occurs at later stage in young adults
compared to first decades [76]. Contrary to these
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dividuals who developed MS and 610 healthy adults, has
shown no cases of MS before EBV infection and similar
rate of MS after seroconversion compared to who were
already EBV positive [77]. These results have clearly
shown the temporal relationship between MS risk and
primary EBV infection, although other alternative inter-
pretations for this exist well. In addition, a meta-analysis
of case-controlled observational studies published in
January 2009 has demonstrated the statistically significant
association between MS and an exposure to EBV by deter-
mining the anti-VCA, anti-EBNA IgG, anti-EBNA-1 IgG
antibodies [78]. The strong association between MS and
anti-EBNA IgG, anti-EBNA-1 IgG antibodies was also
supported by recent large prospective study, which in-
cluded 222 individuals with MS and 444 healthy young
adults) [79]. However, due to the defined subcellular
localization of EBV genes, EBV DNA is hardly detected in
internal compartment including CSF and plasma while it
can easily be detected in saliva [80-83]. Therefore, it is not
surprising that some of the studies failed to identify the
EBV DNA or RNA in CSF and CSF plasma cells [84,85],
but the increased titer of EBV antibody is good evidence
of link between EBV recent infection and MS relapse. The
relationship between EBV and MS has been further
supported by the presence of EBV virus-encoded small
RNA in MS brains [86].
Although compelling evidence linking EBV infection
to MS risk has been described in literature, the under-
lying mechanisms still remain unknown. Several hypoth-
eses that could explain the potential contribution of
EBV to the pathogenesis of MS. Firstly, the EBV specific
CD8+ T cell responses initiate and sustain tissue dam-
age. This idea is supported by Jilek et al. [87], who
showed increase in EBV- specific CD8+ T cells response
at the early stages of MS patients when compared to
healthy adults. But Pender et al., have reported
conflicting results [88] and Gronen et al., failed to locate
any differences at all [89]. So far, according to the au-
thor’s knowledge, there is no study identifying EBV
within the CNS of MS patients. Secondly, EBV triggers
autoimmunity in MS by molecular mimicry between
EBV and myelin antigens [90,91] or infecting auto-
reactive B cells [92]. Furthermore, EBV infection can fa-
cilitate brain infiltration by activating macrophages and
lymphocytes and inducing cytokines [93]. And, lastly
EBV can mediate transactivation of the expression of
HERV elements [94]. Therefore, further experiments are
needed to elucidate the mechanisms how EBV is in-
volved in MS occurrence and its progression.
Varicella zoster virus (VZV) (HHV3)
VZV shares considerable genome homology with HSV.
As discussed in the subsequent sections for H1N1Influenza A viruses, the epidemiology of MS resembles
that of VZV attack [95]. In addition, the antecedent of
VZV appears to be more frequent in MS patients com-
pared to controls [96,97]. Sotelo et al., have demon-
strated more abundant presence of VZV DNA and
VZV-like viral particles (visualized by electron micros-
copy and precipitated with anti-VZV antibodies) in the
cerebrospinal fluid (CSF) of MS patients during relapse
compared to during remission and the control subjects,
suggesting the possible involvement of VZV in the
pathogenesis of MS [98,99]. Recently, they have further
shown the amount of DNA and the number of viral
particles in the CSF of progressive MS patients fell in be-
tween relapse and remission, indicating VZV not only
plays a possible role in MS onset but in its progression
as well [100]. Supporting this, the amount of viral DNA
during relapse was hundreds of times higher in the CSF
than in peripheral blood mononuclear cells (PBMC).
More interestingly, viral DNA as well as viral particles in
the CSF and PBMC decreased dramatically after acute
relapse [98]. However, intriguingly, VZV DNA is not
present in the CSF of MS patients with initial demyelin-
ating event [101], indicating that VZV infection might
take place at some stage of MS rather than before it, and
then plays an accelerating role in MS relapse? Or even
after the occurrence of MS, patient is more susceptible
to VZV. Further experiments at different stages of MS
on a bigger scale are needed to elucidate the nexus
between MS and VZV infection.
Although there are other viruses reported to be
involved in MS, the astounding evidence of HHV par-
ticipation in MS strongly implies either herpes virus
structure, or their lytic reactivation ability, or their im-
mune evasion capability playing an important role in
MS. In addition, a combination of host genetic factors
might also contribute to susceptibility to individual
viruses belonging to this family. This hypothesis can be
only viable when longitudinal experiments with more
specific aims are carried out.
c. H1N1 Influenza a viruses and their possible association
with Parkinson’s disease (PD)
PD is the second most common age-related neurodegen-
erative disorder after AD and it influences more than 1
million people in the US and prevalence is predicted to
triple over the next 50 years due to increase in lifespan.
Its primary characteristic is the loss of dopamine-
secreting cells in the pars compacta region of the
substantia nigra [102]. The cause remains unknown for
majority of PD cases although small percentage of diag-
nosed PD has a genetic causation. Apart for several
possible biological, environmental and genetic causes
linked to PD, it has also been linked to influenza virus
first time after the occurrence of encephalitis lethargica,
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symptoms. Influenza A viruses are negative sense,
single-stranded, segmented RNA viruses, belonging to
the Orthomyxoviridae family. By yearly epidemic, it can
cause up to 500,000 deaths worldwide [103]. So far, it
has caused five flu pandemics. 1918 flu pandemic,
caused by H1N1 subtype, is the most lethal one, which
killed 20–100 million people.
Increased incidence of PD in relation to the 1918
H1N1 influenza A pandemic has been well documented
[104-106],including the incidence in years around 1918
and also the incidence of people who were born around
1918 [105,107,108]. Followed by the 1918 Spanish influ-
enza pandemic, the association of PD with influenza A
has become more evident, yet not completely proven
[109]. It has been shown by Jang et al. [110] that certain
viruses can enter the CNS and are capable of directly
inducing pathological alterations reminiscent of those
observed in Parkinson’s disease. These include, loss of
dopaminergic neurons in the SNpc, long-lasting activa-
tion of microglia in areas infected by virus, as well as
upregulation of alpha-synuclein (with aggregation) in
these same regions. In addition, the possible involvement
of H1N1 as an etiological factor in the development of
Parkinson’s disease has been offered as an alternative
hypothesis due to the presence of Parkinsonian clusters,
where small groups of people in close contact with each
other develop Parkinson’s disease in significantly higher
incidences that would be predicted from the general
population, which affirms this particular influenza virus
could be the etiological cause of the Parkinsonian path-
ologies [110]. At least with the virus Jang et al. studied,
the pattern of infection mimicked the hierarchical pro-
gression of the disease as described by Braak, with infec-
tion starting in the enteric nervous system, traveling into
the CNS via the vagus nerve where it first infects that
solitary and dorsal motor nucleus of X, and then spread-
ing from the brain stem into higher regions of the CNS.
So far, several influenza A viruses have been shown to
be neurotropic [111-116], including H1N1 and H5N1. In
addition, substantia nigra- the most affected brain
region in PD patients, has been shown to be targeted by
A/WSN/33 (H1N1) before its spread in the CNS [117].
Moreover, clear motor deficits have been shown in
poultry [118] as well as humans [119,120] following
H5N1 infection. Using the C57BL/6J mouse, Jang et al.,
has found A/Vietnam/1203/04 H5N1 virus can enter
CNS from peripheral nervous system and induce Parkin-
sonian symptoms (e.g. loss of dopaminergic neurons)
and microglia activation as well as alpha-synuclein phos-
phorylation and aggregation [110]. Recently, Rohn et al.
[121] have also demonstrated the presence of influenza
A virus within the substantia nigra pars compacta
(SNpc) from postmortem PD brain sections. They alsoidentified co-localized influenza A and immune cells
with caspase-cleaved Beclin-1 within the SNpc, which
clearly indicated the role of neuro-inflammation with
influenza A virus’s involvement in PD pathogenesis.
However, no direct correlation between virus and PD
pathology degree and clinical bragging has been made, so
it is hard to conclude how much this virus contributes to
the disease onset and its progression.d. HIV and its role in HIV associated neurocognitive
disorders (HAND)
HAND are common neurological disorders associated
with HIV infection and AIDS. According to current
diagnostic criteria, there is asymptomatic neurocognitive
impairment (ANI), HIV-associated mild neurocognitive
disorder (MND), and HIV-associated dementia (HAD).
Among them, HAD is the most severe form of HAND in
terms of its functional impact. Its neuropathologic features
are perivascular macrophage infiltration, multinucleated
giant cells, activated microglias/microglia nodules, pro-
nounced reactive astrocytosis, myelin pallor on micro-
scopic sections and neuron loss. The pathogenesis of
HAD is not certain yet, but the neurotoxicity of viral
proteins, mononuclear phagocytes activation, cytokine/
chemokine and other soluble factors all show involve-
ment [122,123].
Although with the advent of highly active antiretro-
viral therapy (HAART), the incidence has considerably
dropped initially, the prevalence of HIV-associated cog-
nitive impairment appears to be on the rise due to the
increased life span of HIV+ population. So far, it is still
the most devastating viral-associated neurodegenerative
disease because it impacts more than 30% of HIV-
infected population. Compelling evidence has been
shown that productive HIV infection in the brain is es-
sential for the occurrence and deterioration of HAD
[124]. Recently, it has been shown that HIV-1 can repli-
cate in at least macrophage and CCR5+ T cells within
the CNS in relation to the development and progression
of dementia [125]. Further, the evidence has also demon-
strated that HIV gp120 can induce neuronal apoptosis
by enhancing IA via CXCR4-PKC signaling [126] and
HIV Tat protein can cause neuronal dysfunction by
disrupting miRNAs expression [127].
One of the most striking features of HAD is that it
shares the common anatomical substrate (hippocampus
and substantia nigra) with AD and PD. In addition, it
also shares dopamine deficiency and testosterone defi-
ciency with PD. Also, there is commonality between
HAD and AD in many aspects, such as insulin resist-
ance, raised cholesterol especially in mid-life, and testos-
terone deficiency, the cytokines that are highly secreted,
elevations in lipopolysaccharide concentrations, APOE4
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HIV patients is not surprising.
It has also been reported that some HAD patients
have MS and ALS-like syndromes [129,130]. Our studies
further supported the similarity between HAD and clas-
sical neurodegeneration on proteomic, genomic as well
as transcriptional regulation levels. We have studied the
brain proteome of 9 HIV-associated dementia and 5
HIV non-dementia patients found that 31 proteins to be
significantly altered in certain areas of the brain [1].
Worthy to note, over 90% of the 31 proteins character-
ized from the HIV-infected brains with HAD have
already been identified previously in studies involving
other neurological diseases such as AD, PD, schizophre-
nia, Lewy body dementia, etc. (Table 2). This proteomic
overlap between proteins found in HAD brains and clas-
sical NDs is not only striking, but its also shows how
mechanistically similar are the pathways in viral and
non-viral neurodegenerative diseases. The take home
lesson is that further research in this area, using viruses
as models, can guide us in unraveling mechanisms
underlying neurodegenerative diseases, which is vital to
understand if new strategies for treatment are to be de-
veloped. In addition, they can also determine any role
pathogenic etiologies play in classical NDs in humans.
We have recently examined the genome wide mRNA
and microRNA profiling using HIV+ patients with and
without dementia. The findings indicated the significant
involvement of axon guidance and its downstream sig-
nalling pathways (e.g. MAPK pathway) in HAD patho-
genesis, which concurs with AD and PD as well [155].
Several specific miRNAs we found could differentiate be-
tween HAD and HIV non-dementia group, which inter-
estingly also coincided with the miRNA seen previously in
classical neurodegeneration [156-161]. The reason for the
diversity of HAND is unknown, but it might due to host
genetic factors. HIV might just play prompting role in the
neurodegenerative process. This hypothesis needs to be
elucidated by further studies to compare genetic differ-
ences between HAND patients with different neurodegen-
erative syndromes. However, there is a possibility that the
viral, genetic and environmental factors might participate
in as well. Nonetheless, taken together this is by far the
most compelling evidence at the genomic, proteomic and
gene regulation levels showing viral signatures in classical
neurodegenerative diseases.
e. Amyotrophic lateral sclerosis (ALS)
ALS is fatal neurodegenerative disease characterized by
degeneration or loss of spinal cord and the cortical
neurons. So far the cause for majority cases is unknown
although genetic factors have been reported accounting
for around 5% of all cases. Several viruses have been
reported to be involved in ALS.The involvement of retroviruses, including HIV, has
been shown based on findings, which reported that ALS-
like syndrome to occur in HIV and human T-cell leukemia
virus type-1 (HTLV-1) infection [129,162] and MacGowan
has shown that with antiretroviral therapy, an ALS-like
disorder in HIV-positive patients can abate [163]. Infec-
tion with several other retroviruses infection has also been
documented to cause ALS-like syndromes [164-167]. In
addition, the reverse transcriptase (RT) has been found to
be positive more frequently in ALS patients’ sera com-
pared to that of control and the levels of the activity in
ALS patients were comparable to that in HIV infected pa-
tients [168-170]. Intriguingly, RT activity is hardly detected
in CSF of ALS patients and XMRV sequence is not detect-
able in blood [170]. This result is consistent with another
work [169]. RT is an essential retroviral enzyme product
that allows viral genome to integrate into the host genome
and reproduce its progeny as an active virus upon activa-
tion signal. Therefore, its frequent seropositivity and high
activity in patients with ALS might signal the systemic
retroviral replication. The reason for its absence in CSF is
unknown. The plausible explanation would be RT is re-
leased from lysed cell and CSF is a cell-free compartment.
Recently, expression of distinctive HERV-K pol-like se-
quences has been demonstrated preferentially in pre-
frontal and sensory cortex, areas adjacent to the motor
cortex [171]. Intriguingly, they could only identify the RT
in neurons rather than other cell types.
Possible mechanisms in viral pathogenesis that
explain neurodegenerative disorders
Viral neurotropism
It is well known that many viruses can enter the CNS,
but the mechanism is not well defined. There are two
distinct routes: one is hematogenous dissemination and
the other is neuronal retrograde dissemination. The first
one is better accepted that virus enter the brain by
crossing blood brain barrier via several pathways:
transcytosis; transition by infected endothelial cells,
passage through the blood–cerebral spinal fluid (CSF)
barrier of the choroid plexus, and Trojan horse (utilizing
infected microphage and microglia). This hypothesis is
well documented in HAD and it has been reported in
other viral neurodegenerative disease as well [172]. How-
ever, there is more evidence for the latter pathway re-
cently. It has been shown that influenza virus (A/WSN/33
strain) can enter the CNS via olfactory epithelium [173],
and possibly cranial nerves as well including the vagus
and trigeminal nerves [174,175]. Recently, Harberts et al.
has shown HHV-6 entry into CNS through that pathway
as well [176]. HSV and rabies virus have also been docu-
mented to take this route into CNS [177]. Other study has
shown that A/Vietnam/1203/04 H5N1 virus can enter
CNS from peripheral nervous system [110]. We also found
Table 2 Intersecting pathways and proteins between HIV dementia and classical neurodegenerative diseases
in humans





387 P09972 Fructose-bisphosphate aldolase C [Homo sapiens] 1.69 0.0009 Schizophrenia, bipolar
disorder, and
depression [131]
471 P00338 L-lactate dehydrogenase A chain [Homo sapiens] 1.5 0.039
439 P07195 L-lactate dehydrogenase B chain (LDH) [Homo sapiens] 1.43 0.028
412 P14550 Alcohol dehydrogenase [NADP+][Homo sapiens] 1.36 0.028
605 P60174 Triosephosphate isomerase [Homo sapiens] −1.32 0.02 Neurodegeneration
[132]
581 Q53G35 Phosphoglycerate mutase 1 (Brain) variant (Fragment)
[Homo sapiens]




518 B3KP20 cDNA FLJ30970 fis, clone HEART2000444, highly similar to
Homo sapiens phospholysine phosphohistidine inorganic
pyrophosphate phosphatase (LHPP), mRNA [Homo sapiens]
1.57 0.043 AD [134]
522 P36543 V-type proton ATPase subunit E 1 [Homo sapiens] 1.55 0.0068
658 O75947-2 (ATP5H)Isoform 2 of O75947. [Homo sapiens] 1.48 0.015
587 P47985 Cytochrome b-c1 complex subunit Rieske, mitochondrial
[Homo sapiens]
1.38 0.013
634 O96000 NADH dehydrogenase (ubiquinone) 1 beta subcomplex





363 P15104 Glutamine synthetase[Homo sapiens] 1.85 0.0007 AD[135]





494 P16152 Carbonyl r Carbonyl reductase [NADPH] 1 [Homo sapiens] 2 0.014 AD [138]
Purine metabolism
pathway













738 P16949 Stathmin [Homo sapiens] 1.48 0.031 DS and AD [143,144]
608 P62993 Growth factor receptor-bound protein 2 [Homo sapiens] 1.29 0.04 AD [145]
Calcium signalling
pathway
496 B4DKM5 cDNA FLJ60120, highly similar to Voltage-dependent anion-
selective channel protein 2 [Homo sapiens]*
1.57 0.021
411 P50148 Guanine nucleotide-binding Protein G(o) subunit alpha
[Homo sapiens]




230 Q16555 Dihydropyrimidinase-related protein 2 [Homo sapiens] 1.57 0.025 AD[147]
Parkinson's disease
pathway






189 P11142 Heat shock cognate 71 kDa protein [Homo sapiens] 1.39 0.022 AD [149]
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Table 2 Intersecting pathways and proteins between HIV dementia and classical neurodegenerative diseases
in humans (Continued)
N/A 393 O00154 (ACOT7)Isoform 6 of O00154. [Homo sapiens] 1.64 0.0018
394 Q2TU84 Aspartate aminotransferase [Homo sapiens] 1.51 0.0048
350 P49411 Elongation factor Tu, mitochondrial [Homo sapiens] 1.35 0.008 Infantile
Encephalopathy [150]
723 P61601 Neurocalcin-delta [Homo sapiens]* 1.57 0.043 AD [151]
475 B4DGP9 cDNA FLJ54102, highly similar to Beta-soluble NSF attachment
protein [Homo sapiens]
1.53 0.033
458 P62879 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit
beta-2 [Homo sapiens]
1.73 0.0089 AD [152]
784 A8MVL5 Putative uncharacterized protein PRDX5 [Homo sapiens] −1.88 0.032 AD and parkinson
[153,154]
Note: Most proteins in this table are involved in gene-ontology metabolic process except those proteins marked by *. Zhou et al., [1].
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were heavily involved in HIV productive infection [124].
Our findings are consistent with their findings and we
have hypothesized that HIV might transmit into the brain
from the peripheral nervous system (PNS).
Viruses, inflammation, immune activation and
neurodegeneration
In modern times, we have seen a dramatic increase in
mean life span, which is paralleled by an epidemic of
chronic disease usually associated with ageing [178]. In
spite of the immune privileged status of the CNS, it is
still well known that dynamic immune and inflammatory
responses result from a variety of insults in this compart-
ment, and viral infection accounts for one of them [179].
Inflammatory responses also appear to be the prevalent
triggering mechanism driving tissue damage associated
with different age-related diseases. Age-dependent up-
regulation of the inflammatory response is primarily a
consequence of chronic antigenic stress, which in turn
bombards the innate immune system throughout lifetime
of an individual, and possibly triggering the onset of in-
flammatory disease. A considerable body of experimental
and clinical evidence suggests that the immune system
plays a definitive role, at variable degrees, in almost all
age-related or associated diseases [180].
It is well known that viruses can prime the immune
system to respond aberrantly. Immune and inflammatory
response is a double-edged sword in neurodegenerative
disease depending on the duration of the inflammatory
response. Usually, acute neuro-inflammatory response
includes an immediate and short-lived activation of the in-
nate immune system within the CNS [181,182]. It is bene-
ficial to the CNS, as it minimizes injury, repairs and cleans
the damaged tissue. In contrast, chronic inflammation is
characterized by long-standing activation of microglia
and sustained release of inflammatory mediators, which
lead to increase oxidative and nitrosative stress, subse-
quently perpetuating inflammatory cycle [183]. More-over, chronic neuro-inflammation also contributes to
further prolonged inflammation [179,184]. Therefore,
chronic neuro-inflammation is highly detrimental to
long term neuronal survival compared to major protect-
ive role of acute neuro-inflammation. Several neurode-
generative diseases have been reported to be associated
with chronic neuro-inflammation, including AD, PD,
MS, ALS, etc. [185-188]. Furthermore, the dysregulated
systemic immune responses have been shown to serve
as a signature for early detection of AD [189] and long-
term use of non-steroidal anti-inflammatory drugs
(NSAIDs), in particular ibuprofen, have been proven to
be effective preventing the development of AD [190]. As
a key feature of chronic neuro-inflammation, microglia
activation certainly plays a central role in the patho-
physiology of neurodegenerative diseases. It has been
reported that IL-1 positive activated microglia are co-
localized with both αβ plaques and neurofibrillary
tangles in AD brains and lead to excessive tau phos-
phorylation [188]. The activated microglia also present
in the areas where degenerating motor neurons are
present in both ALS patients and animal models
[191,192]. In addition, positron emission tomography
(PET) studies have confirmed the correlation between the
increased activated microglia in the motor cortex and
upper motor neuron symptoms [193]. Significantly ele-
vated microglia activation in the pons, basal ganglia, stri-
atum, and frontal and temporal cortical regions of PD
brains has also been shown by PET study [194]. It has
been shown that several neurotropic viruses, such as HIV
and HSV, can trigger long-term neuro-immune activation
[195], which might be one of the underlying mechanisms
of viral neurodegenerative diseases.
Neuroinflammation can be either a cause, or a conse-
quence of chronic oxidative stress. Therefore, in this con-
text it is important to mention that oxidative stress is one
of the main features of neurodegenerative diseases and it
binds all neurological and neurodegenerative diseases
together. The oxidative stress causes lipid, protein, and
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nerves. Although the oxidative stress has variety of causes,
such as environmental toxic insults in combination with
genetic factors, it is also attributed to the involvement of
pathogenic etiologies that cause neurodegenerative dis-
eases. Chronic viral and pathogen-mediated proteins in
the presence of excess reactive oxygen species can induce
pathologic changes in neural tissue and lead to chronic
inflammation of the brain, as seen in classical neurode-
generative diseases.
Viruses, innate immunity/adaptive immune system and
neurodegeneration
Innate immunity is an evolutionarily ancient system that
provides organisms with immediately available defense
mechanisms through recognition of pathogen-associated
molecular patterns. Evidence shows that the dysregulation
of innate immune system has been seen broadly in
classical neurodegenerative diseases, such as AD, PD and
Schizophrenia and it is an excellent indication of pathogen-
related footprints on neurodegeneration. Lenhardt et al.,
have shown that in the CNS, specific activation of innate
immunity through a Toll-like receptor 4 (TLR4)-dependent
pathway leads to neurodegeneration [196]. It is important
to iterate that innate immunity is a constitutive component
of the central nervous system (CNS) and heavily depends
on resident myeloid cells, the microglia. Recently emer-
ging evidence suggests that the most abundant glial cell
population of the CNS, the astrocyte, participates in the
local innate immune response triggered as a consequence
of constant insults they go through during infection or in-
flammation and it is important to state that they have been
shown to be reservoirs of HIV-1 and play a significant role
in virus-mediated neurodegeneration. Interestingly, astro-
cytes display an array of receptors, which are involved in
innate immunity, including Toll-like receptors, nucleotide-
binding oligomerization domains, etc.
Fassbender et al., have shown that the detection of CD14
overexpression in brains of APP transgenic mice points
towards the key role of innate immunity receptor CD14 in
significantly contributing to the neuroinflammatory re-
sponses in AD. CD14 recognizes the pattern associated
with the ß-sheet fibrillar conformation of Aß, as this recep-
tor interacts with fibrillar but not with non-fibrillar Aß.
The affinity of fibrillar Aß to CD14 is ∼50-fold lower than
that to LPS. However, since in contrast to LPS the AD
brains contain very high concentrations of Aß fibrils (in
contrast to LPS) for years and decades, it is likely that
even at this submaximal affinity, this interaction is suffi-
cient to maintain a chronic neuro-inflammation. Over-
all, this study provides the basis for possible structural
mimicry between highly hydrophobic fibrillar Aß and
pathogen-associated molecular patterns contributing
to neuro-inflammation in AD and opens the thera-peutically relevant perspective that the enormous pro-
gress being made in the field of innate immunity could
be extended to AD and other neurodegenerative dis-
order research [197]. Previous studies have suggested
that pathogens could be involved in AD too. CD33, one
of four genes found to be significantly associated with
AD in a recent genome-wide association screening (Ber-
tram et al., 2008), is involved in activating the innate
immune system. But perhaps the most prominent ex-
ample of a dementia associated with viral infection is
HIV-associated dementia, which shows the innate im-
mune system involvement and proteomic overlaps with
AD, PD and Schizophrenia (Table 2) [1].Targeting immune system: a new way to treat
neurodegeneration
In the context of innate immune system involvement in
classical neurodegeneration, it is important to mention
that scientists in France and the US discovered that a
type of immune system cell may facilitate the develop-
ment of PD and it has been suggested that targeting part
of the immune system with drugs could be a new way to
treat the disease [198]. In their study, Brochard and
colleagues used postmortem evidence of human patients
to show that CD8+ and CD4+ T cells, but not B cells,
had invaded their brains. They then used mice that had
been given a neurotoxin to induce symptoms of
Parkinson’s (the MPTP mouse model) to show that it
was almost exclusively the CD4+ T cells that arbitrated
the accelerated death of dopamine cells. This only
happened when the FasL cell death triggering protein
was expressed, and not when the IFN-γ inflammatory
cytokine was expressed. This study suggests both acti-
vated microglia and T lymphocytes do make significant
contribution to neurodegeneration in PD.
Elevated T cell responses to specific CNS antigen, or
shift in CD4+ and CD8+ T cell population in the periph-
ery as well as CNS has also been observed in neurodegen-
erative disorders [199-201]. Both CD4 and CD8+ T cells
can be detrimental and protective to the CNS. However,
in that T cells do not significantly accumulate in the brain
undergoing neurodegeneration and more importantly T
cells directed to myelin or neuronal antigens can also be
found in healthy control subjects [202,203], therefore it is
difficult to conclude any direct involvement of T cells as a
causative factor in neurodegenerative diseases. Neverthe-
less, the alteration of CD4+ and CD8+ T cells observed in
the periphery in neurodegenerative diseases indicates that
there is persistent antigenic challenge and T cells are
playing a role in neurodegenerative diseases. It is worthy
to note that the ratio of CD8+ to CD4+ T cell or the shift
to a Tc1/Th1-type immune response may contribute to
the harmful brain inflammatory reaction.
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system in NDs, is the presence of antibodies against
neuronal antigen observed in neurodegenerative diseases
and some of them are pathogenic [2]. The mechanisms
of how these antibodies arise remain unknown. One
plausible explanation is the possible homology between
some pathogen antigens and human neuronal antigens.
Overall, together these studies give further evidence
that the immune system can both protect and attack the
brain. Whether this is a generalized possibility across all
neurodegenerative disorders is an open area of investiga-
tion. Although this study, combined with several other
studies discussed in this review, cumulatively implicate
pathogen and innate immune system involvement in
classical neurodegeneration, which upon further studies
will open the door to developing new treatments that
target the immune system for treating classical neurode-
generative disorders, especially if the NDs occur at
younger age because treating the ageing immune system
may not yield the same effect.Further recent evidence showing the role of immune
system in schizophrenia
In case of schizophrenia, both the unspecific and the
specific arms of the immune system seem to be involved
in the dysfunction of the immune system in schizophrenia.
The unspecific, “innate” immune system shows signs of
over-activation in un-medicated schizophrenic patients, as
indicated by increased monocytes and γδ-cells. Increased
levels of interleukin-6 (IL-6) and the activation of the IL-6
system in schizophrenia might be the result of the activa-
tion of monocytes/macrophages, too. On the other hand,
several parameters of the specific cellular immune system
are blunted, such as, for example, the decreased T helper-1
(TH-1)-related immune parameters in schizophrenic
patients both in vitro and in vivo. It seems that a TH-1/
TH-2 imbalance with a shift to the TH-2 system is associ-
ated with schizophrenia [204]. Three schizophrenia genet-
ics research consortia, each funded in part by NIMH, have
reported separately on their genome-wide association
studies (http://www.genome.gov/20019523) online July 1,
2009, in the journal Nature. However, the SGENE, Inter-
national Schizophrenia (ISC) and Molecular Genetics of
Schizophrenia (MGS) consortia shared their results-
making possible meta-analyses of a combined sample
totaling 8,014 cases and 19,090 controls. Interestingly, all
three studies implicate an area of Chromosome 6 (6p22.1),
which is known to harbor genes involved in immunity and
controlling how and when genes turn on and off. This
hotspot of association might help to explain how environ-
mental factors and infection by pathogens affect risk for
schizophrenia. Recently, genetic data from multiple large
cohorts of patients were published in ‘Nature’ showing thatdifferent gene loci located on chromosome 6p22.1 are the
most probable susceptibility genes for schizophrenia [3].
This region includes several genes of interest, which are re-
lated to the immune function. The strongest evidence for
association was observed in or near a cluster of histone
protein genes which could be relevant through their roles
in regulation of DNA transcription or repair, i.e. in epi-
genetics [205], or their direct role in antimicrobial
defense [206]. Moreover, several genes of the HLA com-
plex, which regulate the immune function and already
earlier have been discussed to be involved in schizo-
phrenia, are located in these regions [207].
Although an immune dysfunction and the involve-
ment of infectious agents in the pathophysiology of
schizophrenia are discussed since decades, the field
never came into the mainstream of research. These gen-
etic findings and further recent interesting observations,
however, may contribute shifting research into the dir-
ection of immunological alterations and inflammation
as cause for schizophrenia. Although the involvement of
infectious agents has long been suspected in schizo-
phrenia, results from animal models indicate that the
immune response determines the risk for schizophrenia
[208].
It is well known that the molecules participating in
both innate and adaptive immune responses have been
shown to be induced in a wide diversity of neurological
disorders, which include AD, MS, HD, PD, and ALS all
discussed in this review. The recent evidence on im-
mune response within the brain actually points towards
host immune mechanisms could be the actual culprit or
in other word etiologically linked to the manifestation of
neurodegenerative diseases. Further, this also suggests
that the primary causes of a large majority of neurologic
disorders seen in humans could originate outside the
central nervous system. Some infectious agents are
known to gain entry into the CNS within infected migra-
tory macrophages, which traverse the blood brain barrier
by transcytosis or by intra-neuronal transfer from per-
ipheral nerves. In case of various viruses, especially the
ones associated with NDD, the systemic nature of these
pathogens is able to trigger immune responses, along
with affecting the immune system and other organ
systems including the brain, resulting in neurologic
manifestation.
Although the underlying mechanisms of HAD are still
uncertain, the cumulative evidence has pointed out that
HIV might cause immune-senescence. First of all, it is
evident that the age of HIV+ patients who manifest
dementia and Alzheimer’s disease, which is 15 years
(50–52 years) less than HIV- individuals who manifest
AD (Average age 65–85). Second, apart from dementia,
HIV can also lead to other aged diseases, which is closely
related to immune-senescence, such as cardiovascular
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oxidative phosphorylation pathways [209]. Third, it has
been shown that HIV infection can induce T lymphocytes
immune-senescence, which is indicated by deteriorated
shortening of telomeres in CD8+ CD28- T cells while no
significant change in CD4+ T cells [210,211] and this is
highly similar with what has been seen in the elderly. In
addition, a marker of immunosenescence, CD57, can also
be detected during initial stage of HIV infection [212].
Furthermore, HIV infection can induce similar alterations
to innate immune cells, including monocytes, NK cells,
dendritic cells and neutrophils, compared to that induced
by ageing [213]. In this context it is important to men-
tion that even though HIV shares anatomical, clinical
and proteomic overlaps with both AD and PD, the
involvement of virus or any pathogen in classical
neurodegeneration has not been proven.Dysregulated metabolic and transport machinery in NDs:
evidence for viral interference
It is well known that metabolic pathways have an integral
involvement in neurodegenerative process in humans.
With ageing, there is up regulation of both oxidative stress
and metabolic pathways in the human brain and more so
during the manifestation of neurological disease. The sig-
nificant dysregulation of both these pathways is apparent
in a variety of viruses, which include, HIV, HCV, Influ-
enza, etc. It has been shown that the impairment of energy
metabolism can exacerbate synaptic dysfunction, neuronal
injury, which together may lead to neurodegenerative dis-
orders [214]. Viruses are completely reliant on their host’s
cellular nucleic acids, proteins and membrane, as well as
energy to enable viral synthesis. Disturbance/dysregulation
of several core metabolic pathways have been reported by
viral infections, including glycolysis and lipid metabolism,
which all play a very important role in neurodegenerative
diseases [215]. Viruses use several means to interfere with
host metabolism, including manipulating host gene ex-
pression; inhibiting host cellular process (such as RNA
and protein synthesis); impairing mitochondrial function
and interfering ATP production [215]. Indirect evidence
also comes neuro-proteomic analysis of HIV+ patients
with and without dementia, which showed the first
evidence that >90% of the protein candidates identified in
the HAD brains, particularly in the oxidative phosphoryl-
ation (OXPHOS) and glycolysis pathways appear also to
over represent in non-viral mediated neurodegenerative
diseases, such as vascular dementia, AD, PD and amyo-
trophic lateral sclerosis (ALS) [1], a study which is highly
significant as it shows the ultimate footprints of a virus on
neurodegenerative disease and its overlap with classical
forms of neurodegeneration has considerable potential for
treatments for NDs in humans.Viral infection also interferes with host transport
machinery, whose alterations are cardinal feature of
neurodegenerative diseases, eg. neurofibrillary changes
in AD, Lewy bodies in PD, and different types of fila-
mentous inclusion bodies in motor neuron disease. It
has been well documented that viral proteins can modu-
late the structure and function of the actin cytoskeleton
to initiate, sustain and spread infections [216].
Conclusions
Based on all the evidence and controversies discussed in
this review, one single fact emerges out suggesting that
viruses can be causative agents or at least co-factors of
some of neurodegenerative diseases, if not all. Even
though the virus involvement in human NDs is hotly
debated and disputed, the take home message from the
studies complied in this review is the mechanistic simi-
larities between viral and non-viral neurodegenerative
diseases, which further imply that viruses can act as
excellent models in understanding neurodegeneration in
humans. A critical understanding of these overlaps
between viral and non-viral NDs may lead to new strat-
egies to treat human NDs. But there is still a lot of work
to be done before pathogen link to classical neurodegen-
erative diseases becomes fully concrete.
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